- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02555085
Single Ascending Doses of BIIB063 in Healthy Volunteers
17. April 2017 aktualisiert von: Biogen
Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers
The primary objective of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) doses and a single subcutaneous (SC) dose of BIIB063 in healthy volunteers.
The secondary objectives of the study are to estimate the PK parameters of single ascending IV doses of BIIB063; to estimate the PK parameters and absolute bioavailability (F) of a single SC dose of BIIB063; and to evaluate the immunogenicity of single ascending doses of BIIB063.
Studienübersicht
Studientyp
Interventionell
Einschreibung (Tatsächlich)
29
Phase
- Phase 1
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
West Yorkshire
-
Leeds, West Yorkshire, Vereinigtes Königreich, LD2 9LH
- Research Site
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 55 Jahre (Erwachsene)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Beschreibung
Key Inclusion Criteria:
- All male subjects and all female subjects of childbearing potential must practice at least 1 highly effective method of contraception (i.e., contraceptive measure with a failure rate of <1% per year; estrogen-containing contraceptives are prohibited) during the study and be willing and able to continue contraception for 4 months after being dosed with study treatment. Male subjects must also be willing to refrain from sperm donation for at least 4 months after the last dose of study treatment. Male subjects must not have unprotected sexual intercourse with a female who is pregnant or breastfeeding during the study.
- Must have a body mass index between 18 and 30 kg/m2, inclusive.
- Must be in good health as determined by the Investigator, based on medical history, physical examination, and 12-lead ECG.
Key Exclusion Criteria:
- History of or positive test result at screening for human immunodeficiency virus, hepatitis C virus antibody, or hepatitis B virus (defined as positive for hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb]).
- History of any clinically significant cardiac, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as determined by the Investigator.
- Personal or family history of cardiovascular disease under the age of 50 years, inherited disorder of coagulation (e.g., Factor V Leiden, protein C or S deficiency), or anti-phospholipid Ab syndrome (APS).
- History of meningococcal vaccination or meningococcal meningitis, or history of hypersensitivity to single components of meningococcal vaccines (including MENVEO), any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine.
- History of tuberculosis (TB) or positive QuantiFERON®-TB Gold test
- Personal history of thromboembolic events
- Treatment with any prescription or over-the-counter medication within 14 days prior to randomization (excluding vitamins, dietary supplements, herbal preparations, progestin-only birth control, and paracetamol up to 4 g/day for no more than 5 consecutive days).
- Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 3 months
- Current enrollment or a plan to enroll in any other drug, biologic or device clinical study, or treatment with an investigational drug or approved therapy for investigational use within 3 months
- Blood donation (1 unit or more) within 3 months prior to randomization.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: IV Dose 1
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Einzelne Dosis
|
|
Experimental: IV Dose 2
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Einzelne Dosis
|
|
Experimental: IV Dose 3
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Einzelne Dosis
|
|
Experimental: IV Dose 4
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Einzelne Dosis
|
|
Experimental: IV Dose 5
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Einzelne Dosis
|
|
Experimental: IV Dose 6
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Einzelne Dosis
|
|
Experimental: IV Dose 7
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
|
Single ascending IV dose
Einzelne Dosis
|
|
Experimental: SC Dose
Single SC dose or matching placebo
|
Single ascending IV dose
Einzelne Dosis
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Number of participants with clinically significant laboratory assessment abnormalities
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Number of participants with clinically significant Vital sign abnormalities
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Number of participants with clinically significant physical examination abnormalities
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Change in antibody titers of vaccine immunization for tetanus
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Change in antibody titers of vaccine immunization for diphtheria
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Change in antibody titers of vaccine immunization for pneumococcus
Zeitfenster: Up to week 12
|
Up to week 12
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Maximum observed concentration (Cmax)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Time to reach maximum observed concentration (Tmax)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Terminal elimination half-life (t1/2)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Clearance (CL)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of single-ascending IV doses of BIIB063: Volume of distribution at steady state (Vss)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Maximum observed concentration (Cmax)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Time to reach maximum observed concentration (Tmax)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Terminal elimination half-life (t1/2)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063 Apparent total body clearance (CL/F)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Apparent volume of distribution during terminal elimination phase (Vz/F)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
PK parameter of a single SC dose of BIIB063: Absolute Bioavailability (F)
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Number of participants with positive serum anti-BIIB063 antibodies
Zeitfenster: Up to week 12
|
Up to week 12
|
|
Percentage of participants with positive anti-BIIB063 titers within 12 weeks after administration of BIIB063
Zeitfenster: Up to 12 weeks
|
Up to 12 weeks
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
30. September 2015
Primärer Abschluss (Tatsächlich)
1. Juni 2016
Studienabschluss (Tatsächlich)
1. Juni 2016
Studienanmeldedaten
Zuerst eingereicht
27. August 2015
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
17. September 2015
Zuerst gepostet (Schätzen)
21. September 2015
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
18. April 2017
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
17. April 2017
Zuletzt verifiziert
1. April 2017
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- 234HV101
- 2015-001283-18 (EudraCT-Nummer)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .